Literature DB >> 23073726

Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.

Tammi Schaeffer1.   

Abstract

The increased use of opioid pain medication has been mirrored by the increased misuse and abuse of these drugs. As part of a multidisciplinary approach to this epidemic, pharmaceutical companies, with the encouragement of the Food and Drug Administration, have increased the development of abuse-deterrent formulations. While all have the goal of treating pain while mitigating misuse and abuse, there are different technologies utilized to impart the abuse-deterrent properties. The goal of this paper is to review the basis of abuse-deterrent formulations, the different types and approaches of some of the abuse-deterrent products, and their current regulatory status in the USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073726      PMCID: PMC3550267          DOI: 10.1007/s13181-012-0270-y

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  40 in total

Review 1.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

2.  Development of opioid formulations with limited diversion and abuse potential.

Authors:  Paul J Fudala; Rolley E Johnson
Journal:  Drug Alcohol Depend       Date:  2006-03-24       Impact factor: 4.492

3.  Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology.

Authors:  Kuei-Meng Wu; James G Farrelly
Journal:  Toxicology       Date:  2007-04-21       Impact factor: 4.221

4.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.

Authors:  Theodore J Cicero; James A Inciardi; Alvaro Muñoz
Journal:  J Pain       Date:  2005-10       Impact factor: 5.820

5.  Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

Authors:  P J Fudala; E Yu; W Macfadden; C Boardman; C N Chiang
Journal:  Drug Alcohol Depend       Date:  1998-03-01       Impact factor: 4.492

6.  Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

Authors:  Hannu Alho; David Sinclair; Erkki Vuori; Antti Holopainen
Journal:  Drug Alcohol Depend       Date:  2006-10-19       Impact factor: 4.492

Review 7.  PTI-821: sustained-release oxycodone using gel-cap technology.

Authors:  Lynn R Webster
Journal:  Expert Opin Investig Drugs       Date:  2007-03       Impact factor: 6.206

8.  Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation.

Authors:  Steven D Passik; Lon Hays; Nina Eisner; Kenneth L Kirsh
Journal:  J Pain Palliat Care Pharmacother       Date:  2006

9.  Pentazocine--naloxone: another "addiction-proof" drug of abuse.

Authors:  H W Lahmeyer; R J Craig
Journal:  Int J Addict       Date:  1987-11

10.  Buprenorphine and naloxone alone and in combination in opioid-dependent humans.

Authors:  K L Preston; G E Bigelow; I A Liebson
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more
  6 in total

1.  [Acute pain management in patients with drug dependence syndrome].

Authors:  J Quinlan; F Cox
Journal:  Schmerz       Date:  2018-02-08       Impact factor: 1.107

Review 2.  Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety.

Authors:  Kyle Simon; Stacey L Worthy; Michael C Barnes; Benjamin Tarbell
Journal:  Ther Adv Drug Saf       Date:  2015-04

3.  The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain.

Authors:  Joseph V Pergolizzi; Robert Taylor; Robert B Raffa
Journal:  Adv Ther       Date:  2015-05-31       Impact factor: 3.845

4.  Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France.

Authors:  Salim Mezaache; Patrizia Carrieri; Laélia Briand-Madrid; Virginie Laporte; Alain Morel; Daniela Rojas Castro; Perrine Roux
Journal:  Harm Reduct J       Date:  2021-01-19

5.  Acute pain management in patients with drug dependence syndrome.

Authors:  Jane Quinlan; Felicia Cox
Journal:  Pain Rep       Date:  2017-07-27

6.  Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).

Authors:  Ernest A Kopecky; Alison B Fleming; Naama Levy-Cooperman; Melinda O'Connor; Edward M Sellers
Journal:  J Clin Pharmacol       Date:  2016-11-01       Impact factor: 3.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.